Abstract:Introduction.
Media reporting of clinical trials impacts patient-oncologist interactions. We sought to characterize the accuracy of media and Internet reporting of practice-changing clinical trials in oncology.
Materials and Methods.
The first media articles referencing 17 practice-changing clinical trials were collected from 4 media outlets: newspapers, cable news, cancer websites, and industry websites. Measured outcomes we… Show more
“…3 Additionally, providing outcomes directly to participants is more accurate than the often sensationalized, incomplete, or exaggerated claims purported by mainstream media. 9–12 However, some authors have identified potential pitfalls of disclosure, including emotional distress from negative results, 13 release of premature outcomes, and the time or cost constraints that limit the ability to disclose information effectively. 13–15…”
Most clinical trial participants feel they have a right to study result disclosure, regardless of trial outcome. In-person visits are preferred for negative results, but more feasible alternatives such as letters were still acceptable for the majority of participants. However, Internet-based disclosure was not acceptable to most participants in oncology trials. Time and cost allocations for result disclosure should be considered during grant and ethics board applications, and clear guidelines are required to help researchers share the results with patients.
“…3 Additionally, providing outcomes directly to participants is more accurate than the often sensationalized, incomplete, or exaggerated claims purported by mainstream media. 9–12 However, some authors have identified potential pitfalls of disclosure, including emotional distress from negative results, 13 release of premature outcomes, and the time or cost constraints that limit the ability to disclose information effectively. 13–15…”
Most clinical trial participants feel they have a right to study result disclosure, regardless of trial outcome. In-person visits are preferred for negative results, but more feasible alternatives such as letters were still acceptable for the majority of participants. However, Internet-based disclosure was not acceptable to most participants in oncology trials. Time and cost allocations for result disclosure should be considered during grant and ethics board applications, and clear guidelines are required to help researchers share the results with patients.
“…Other consumer and patient sources – In a systematic review of studies assessing the quality of online health information for consumers, Eysenbach et al found 55 of 79 studies (70%) had concluded that quality was a problem. 71 In more recently published studies, others have found problems with the information on anti-vaccination websites, 72 cancer and oncological industry websites, 73 websites for clinics offering weight loss surgery, 74 and websites for fertility centres. 75 In their study of media coverage of practice-changing clinical trials in oncology, Andrew et al .…”
Background Many studies have assessed the quality of news reports about the effects of health interventions, but there has been no systematic review of such studies or meta-analysis of their results. We aimed to fill this gap (PROSPERO ID: CRD42018095032). Methods We included studies that used at least one explicit, prespecified and generic criterion to assess the quality of news reports in print, broadcast, or online news media, and specified the sampling frame, and the selection criteria and technique. We assessed criteria individually for inclusion in the meta-analyses, excluding inappropriate criteria and criteria with inadequately reported results. We mapped and grouped criteria to facilitate evidence synthesis. Where possible, we extracted the proportion of news reports meeting the included criterion. We performed meta-analyses using a random effects model to estimate such proportions for individual criteria and some criteria groups, and to characterise heterogeneity across studies. Results We included 44 primary studies in the qualitative summary, and 18 studies and 108 quality criteria in the meta-analyses. Many news reports gave an unbalanced and oversimplified picture of the potential consequences of interventions. A limited number mention or adequately address conflicts of interest (22%; 95% CI 7%-49%) (low certainty), alternative interventions (36%; 95% CI 26%-47%) (moderate certainty), potential harms (40%; 95% CI 23%-61%) (low certainty), or costs (18%; 95% CI 12%-28%) (moderate certainty), or quantify effects (53%; 95% CI 36%-69%) (low certainty) or report absolute effects (17%; 95% CI 4%-49%) (low certainty). Discussion There is room for improving health news, but it is logically more important to improve the public’s ability to critically appraise health information and make judgements for themselves.
“…In a study of 17 practice-changing clinical trials, it has been demonstrat- ed that a media reporting score, defined as a measure of completeness of information detailed in media articles, showed most thorough reporting for industry, followed by cancer websites (including www.ascopost.com, www. cancer.org and www.cancer.gov), newspapers as well as cable news [14]. The most frequently excluded items from media coverage were study limitations, followed by exclusion criteria, adverse events, and conflicts of interest.…”
Section: Discussionmentioning
confidence: 99%
“…However, there are several important limitations of published studies. First, only a small number of RCTs have been explored and searching of media coverage was not systematic and therefore likely incomplete [14,15]. Second, analyses included primarily media reporting from eminent scientific meetings and were not based on research findings published in peer-reviewed medical journals.…”
Section: Discussionmentioning
confidence: 99%
“…Unfortunately, it has been demonstrated that quality of reporting is variable with some sources providing neither clear referencing nor a statement of the methodologic strength of evidence or the maturity and quality of the data. Deficiencies in reporting have been described particularly for the lay press such as industry websites, newspapers, and cable news [14].…”
Background: Limited data exist about the role of the lay media in the dissemination of results of randomized controlled trials (RCTs) in common cancers. Methods: Completed phase III RCTs evaluating new drugs in common cancers between January 2005 and October 2016 were identified from ClinicalTrials.gov. Lay media reporting was identified by searching LexisNexis Academic. Scientific reporting was defined as presentation at an academic conference or publication in full. Associations between reporting in the lay media before scientific reporting and study design and sponsorship were evaluated using logistic regression. Results: Of 180 RCTs identified, 52% were reported in the lay media and in 27%, lay media reporting occurred before scientific reporting with an increasing trend over time (p = 0.009). Reporting in the lay media before scientific reporting was associated with positive results (OR: 2.10, p = 0.04), targeted therapy compared to chemotherapy (OR: 4.75, p = 0.006), immunotherapy compared to chemotherapy (OR: 7.60, p = 0.02), and prostate cancer compared to breast cancer (OR: 3.25, p = 0.02). Conclusions: Over a quarter of all RCTs in common cancers are reported in the lay media before they are reported scientifically with an increasing proportion over time. Positive trials, studies in prostate cancer, and trials of immunotherapy are associated with early reporting in the lay media.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.